Blood vessel invasion is a major feature and a factor of poor prognosis in sarcomatoid carcinoma of the lung

作者：Vieira Thibault; Antoine Martine; Ruppert Anne Marie; Fallet Vincent; Duruisseaux Michael; Leprieur Etienne Giroux; Poulot Virginie; Rabbe Nathalie; Sclick Laurene; Beau Faller Michele; Lacave Roger; Lavole Armelle; Cadranel Jacques; Wislez Marie^*

来源：Lung Cancer, 2014, 85(2): 276-281.

DOI：10.1016/j.lungcan.2014.06.004

• Non-small-cell lung carcinoma
• Sarcomatoid carcinoma
• Biomarker
• Blood vessel invasion
• Prognosis
• Molecular classification

Objectives: Pulmonary sarcomatoid carcinomas (SC) are highly disseminated types of non-small-cell lung carcinoma. Their prognosis is poor. New therapeutic targets are needed to improve disease management.
Materials and methods: From 1995 to 2013, clinical and survival data from all consecutive patients with surgically treated SC were collected. Pathological and biomarker analyses were performed: TTF1, P63, c-MET and ALK expression (immunohistochemistry), PAS staining, ALK rearrangement (FISH), and EGFR, KRAS, HER2, BRAF, PIK3CA, and MET genes mutations (PCR).
Results: Seventy-seven patients were included. Median age was 61 years (53-69). Histological subtypes were pleomorphic carcinoma (78%), carcinosarcoma (12%), and giant-cell and/or spindle-cell carcinoma (10%). Blood vessel invasion (BVI) was present in 90% of cases. Morphology and immunohistochemistry were indicative of an adenocarcinoma, squamous, and adenosquamous origin in 41.5%, 17% and 11.5%, respectively, 30% remained not-otherwise-specified. KRAS, PIK3CA, EGFR, and MET mutations were found in 31%, 8%, 3%, and 3%, respectively. No tumors had HER2 or BRAF mutations, or ALK rearrangement, whereas 34% had a c-MET positive score. Five-year overall survival (OS) was 29% for the whole population. At multivariate analysis, tumor size <50 mm (HR=1.96 [1.04-3.73], p=0.011), no lymph-node metastasis (HR=3.25 [1.68-6.31], p<0.0001), no parietal pleural invasion (HR=1.16 [1.06-1.28], p=0.002), no BVI (HR=1.22 [1.06-1.40], p=0.005), and no squamous component (HR=3.17 [1.48-6.79], p=0.01) were associated with longer OS. Biomarkers did not influence OS.
Conclusion: Dedifferentiation in NSCLC could lead to SC and an epithelial subtype component could influence outcome. BVI was present in almost all SCs and was an independent factor of poor prognosis.

• 出版日期2014-8